aibioScienture reports Q1 2026 revenue of $56 thousand and a 95.6% gross margin
Tickers SCNX
Revenue rose 449% from a year earlier on more Arbli orders. The company also reported $11.0 million of non-dilutive debt financing.
Key facts
- Company
- Scienture Holdings, Inc. (NASDAQ: SCNX)
- News type
- Company Updates
- Primary source
- Scienture Holdings, Inc. 8-K (2026-05-22)
Scienture Holdings, Inc. reported its financial results for the three months ended March 31, 2026, in a business update dated May 18, 2026. The company furnished the release to the SEC in a Form 8-K. Revenue was approximately $56 thousand, up 449% from the prior-year quarter, reflecting incremental product orders for Arbli. The release also described an $11.0 million non-dilutive debt financing.
The quarter in numbers
Revenue for the quarter was approximately $56 thousand, compared with approximately $10 thousand a year earlier. The release says the increase reflects wholesale distribution sales of SCN-102, sold as Arbli, following its commercial launch. It also reflects incremental product orders in addition to the initial launch quantities ordered in the fourth quarter of 2025.
Gross profit rose to approximately $54 thousand, compared with approximately $673 in the prior-year period, a year-over-year increase of approximately 7900%. Gross margin expanded to approximately 95.6%, from approximately 6.6% a year earlier.
Total operating expenses were approximately $3.56 million, compared with approximately $3.57 million, a slight decrease of approximately 0.2%. Net loss was approximately $3.4 million, compared with approximately $3.1 million in the prior-year period.
Narasimhan Mani, President and Co-CEO, said the results "reflect the early progress of our commercialization strategy." He added that the company saw continued month-over-month growth in both prescriptions and units sold for Arbli during the quarter.
Products and commercial progress
Arbli is a liquid formulation of losartan potassium that the release describes as FDA-approved for the treatment of hypertension in patients greater than six years old. It is also approved for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. The release says it comes in a 165 mL bottle, does not require refrigeration and has a shelf life of 24 months at room temperature.
During the quarter the USPTO granted a third patent covering Arbli, which the company says extends its expected market exclusivity through 2041.
For REZENOPY (naloxone HCl) nasal spray 10 mg, the company received an Orange Book-listable patent. The release describes the product as the highest-dose FDA-approved naloxone HCl nasal spray for emergency opioid overdose treatment. The company also formalized multiple GPO agreements for REZENOPY. It says these expand access to over 5,000 healthcare institutions and reach approximately 60% of the U.S. institutional market, including first responders, EMS providers and rehabilitation centers. The company's sales force is scheduled to begin operations on June 1, 2026, targeting key accounts and purchasing organizations.
The debt and the limits of the progress
The company said it secured $11.0 million in what it calls non-dilutive debt financing. The label is the company's, and the release gives no interest rate, maturity, covenants, lender or conversion terms, so the cost and the repayment burden are not visible. Debt must be repaid, and it arrives while the business is still small: quarterly revenue of about $56 thousand sits against operating expenses of about $3.56 million, and the net loss of about $3.4 million was larger than the $3.1 million a year earlier. Co-CEO Shankar Hariharan said the financing helps position the company toward anticipated profitability in 2027, and Mani said Arbli and the anticipated REZENOPY launch should matter in the second half of 2026. Both are expectations, not results, and REZENOPY had not yet launched.
Background from the annual report
Scienture is a Delaware corporation headquartered in Commack, New York. Its annual report amendment reports 40,630,815 shares of common stock outstanding on April 30, 2026. For 2025, the company reported research and development expense of $2.0 million, compared with $2.2 million in 2024. It reported a net loss of $41.5 million for 2025, compared with net income of $9.1 million for 2024. Cash used in operations was $13.4 million in 2025, compared with $14.3 million in 2024.